SCHEDULE 13G/A: Frazier Life Sciences Funds and Principals Update Significant Stake in Erasca, Inc. to 8.0%

Frazier Life Sciences Public Fund and affiliated entities, along with key principals, have filed an amended Schedule 13G/A, disclosing a collective beneficial ownership of 8.0% in Erasca, Inc.'s common stock as of March 31, 2025.

Summary

• Frazier Life Sciences Public Fund, L.P. and its general partners (FHMLSP, L.P. and FHMLSP, L.L.C.) collectively beneficially own 14,929,001 shares of Erasca, Inc. common stock, representing 5.3% of the class.
• Frazier Life Sciences Public Overage Fund, L.P. and its general partners (FHMLSP Overage, L.P. and FHMLSP Overage, L.L.C.) collectively beneficially own 2,373,243 shares, representing 0.8% of the class.
• Frazier Life Sciences X, L.P. and its general partners (FHMLS X, L.P. and FHMLS X, L.L.C.) collectively beneficially own 1,670,580 shares, representing 0.6% of the class.
• Frazier Life Sciences XI, L.P. and its general partners (FHMLS XI, L.P. and FHMLS XI, L.L.C.) collectively beneficially own 3,603,027 shares, representing 1.3% of the class.
• James N. Topper and Patrick J. Heron each beneficially own 22,575,851 shares, representing 8.0% of the class, through shared voting and dispositive power over shares held by Frazier Life Sciences Public Fund, Public Overage Fund, X, and XI.
• Albert Cha and James Brush each beneficially own 17,302,244 shares, representing 6.1% of the class, through shared voting and dispositive power over shares held by Frazier Life Sciences Public Fund and Public Overage Fund.
• Daniel Estes beneficially owns 3,603,027 shares, representing 1.3% of the class, through shared voting and dispositive power over shares held by Frazier Life Sciences XI, L.P.
• The percentages are calculated based on 283,265,716 shares of Erasca, Inc. Common Stock outstanding as of March 13, 2025, as reported in the Issuer's Annual Report on Form 10-K filed on March 20, 2025.
• The filing is an amendment (Amendment No. 1) to a previous Schedule 13G statement.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory filing disclosing beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by institutional investors in a publicly traded biotechnology company, Erasca, Inc. Such filings provide transparency regarding significant shareholder positions, which is standard practice in the life sciences sector where institutional investment is common.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.

Key Dates

Keywords

Erasca Inc., Frazier Life Sciences, Schedule 13G/A, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Fund, Biotechnology, Healthcare Investment